List Title | APhA DrugInfoLine

Nephrology

SORT BY: Most Recent Most Viewed

July 1, 2007

Anemia, ESA guidelines under revision

READ

PREVIEW
Anemia management in patients with chronic kidney disease—especially the recommended target hemoglobin at which erythropoiesis stimulating agents (ESA) such as epoetin alfa (Epogen—...
March 1, 2007

Aliskiren: Oral direct renin inhibitor for hypertension

READ

PREVIEW
Aliskiren (Tekturna—Novartis) is the first available oral direct renin inhibitor. It is effective in significantly reducing blood pressure (BP) alone or in combination with other...
February 1, 2007

Erythropoietic stimulation in oncology: Avoid outside chemotherapy

READ

PREVIEW
In a large, randomized, multicenter clinical trial, darbepoetin alfa (Aranesp—Amgen) administered to patients with anemia of cancer who were not receiving chemotherapy failed to reduce red...
February 1, 2007

Cancer incidence increased in kidney transplant candidates, recipients

READ

PREVIEW
A large population-based study shows a slightly increased incidence of a variety of cancers, especially those with viral components in their etiologies, among patients in the years leading up to...

Pages

Medication Monitor

RSS Follow Medication Monitor on Twitter Follow APhA Druginfoline on Twitter

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.